Research Analysts’ Weekly Ratings Updates for Novogen (KZIA)

Novogen (NASDAQ: KZIA) recently received a number of ratings updates from brokerages and research firms:

• 10/30/2026 – Novogen is now covered by Needham & Company LLC. They set a “buy” rating and a $27.00 price target on the stock.
• 10/21/2026 – Novogen is now covered by Guggenheim. They set a “buy” rating and a $35.00 price target on the stock.
• 10/20/2026 – Novogen is now covered by Leerink Partners. They set an “outperform” rating and a $30.00 price target on the stock.
• 10/15/2026 – Novogen had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 9/10/2026 – Novogen had its “buy” rating reaffirmed by BTIG Research. They now have a $40.00 price target on the stock.

Novogen Stock Down 11.6%

Shares of NASDAQ KZIA traded down $0.94 during trading on Thursday, hitting $7.14. The company had a trading volume of 186,158 shares, compared to its average volume of 229,028. Novogen Limited has a 12 month low of $4.86 and a 12 month high of $17.40. The stock has a 50 day simple moving average of $9.91 and a 200 day simple moving average of $10.50.

Novogen Limited was an Australian biotechnology company that developed novel therapies for cancer. The company focused on small-molecule drug candidates designed to target biological pathways involved in tumor growth and survival, with an emphasis on cancers that have limited treatment options.

In 2016, Novogen changed its name to Kazia Therapeutics Limited and continued its oncology research under the Kazia name. Its principal development program became paxalisib, an investigational PI3K/mTOR inhibitor being studied for brain cancers, including glioblastoma and brain metastases.